Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013).

Incidence data on pertussis cases in Italy do not show pertussis resurgence as recently described in other European countries. The aim of this study was to determine the seroprevalence of IgG antibodies to pertussis toxin (PT-IgG) in selected adult age groups, who can serve as a reservoir of Bordetella pertussis and be responsible for onward transmission to vulnerable infants. The seroprevalence of PT-IgG was studied in sera collected in 2012-2013 in three age groups: 20-29 years and 30-39 years (reproductive age), and ≥60 years. These data were compared to those from sera collected in similar age groups in 1996-1997. More than 80 % of the adult population analysed in the 2012-2013 group presented detectable levels of PT-IgG (>5 IU ml-1). PT-IgG titres of 50-99 IU ml-1, considered indicative of infection in the last few years, and PT-IgG titres of  ≥100 IU ml-1, considered indicative of recent infection (i.e.within the last year), reached 9.1 % [95 % confidence interval (CI) 6.9-11.3‌  %; 58/639] and 5 % (95 % CI 3.3-6.7 %; 32/639) seroprevalence, respectively. Notably, the proportion of subjects with a seroprevalence indicative of recent infection increased significantly from 9.3 % (95 % CI 7.5-11.1 %; 96/1037) in 1996-1997 to 14.1 % (95 % CI 11.4-16.8 %; 90/639) in 2012-2013. Overall, our data clearly indicate a significant increase in the circulation of B. pertussis in adults in Italy; therefore, it is likely that the statutory notification system underestimates the real incidence of the disease. These findings have implications for preventive strategies.

[1]  G. Fedele,et al.  T-cell immune responses to Bordetella pertussis infection and vaccination. , 2015, Pathogens and disease.

[2]  Qiushui He,et al.  Seroprevalence studies of pertussis: what have we learned from different immunized populations. , 2015, Pathogens and disease.

[3]  H. Goossens,et al.  Prevalence, diagnosis, and disease course of pertussis in adults with acute cough: a prospective, observational study in primary care , 2015, The British journal of general practice : the journal of the Royal College of General Practitioners.

[4]  E Rizzuto,et al.  Epidemiology of pertussis in Italy: disease trends over the last century. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  S. Plotkin The pertussis problem. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Jeff F. Miller,et al.  Bordetella pertussis pathogenesis: current and future challenges , 2014, Nature Reviews Microbiology.

[7]  A. Linneberg,et al.  Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark , 2013, Epidemiology and Infection.

[8]  P. Melin,et al.  Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012 , 2013, Epidemiology and Infection.

[9]  A. Tozzi,et al.  Attitude of Italian physicians toward pertussis diagnosis , 2013, Human vaccines & immunotherapeutics.

[10]  E. Chiappini,et al.  Pertussis re-emergence in the post-vaccination era , 2013, BMC Infectious Diseases.

[11]  K. Macartney,et al.  Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. , 2013, Vaccine.

[12]  J. Mertsola,et al.  High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  P. van Damme,et al.  Rationale for pertussis booster vaccination throughout life in Europe. , 2011, The Lancet. Infectious diseases.

[14]  F. Mooi,et al.  Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis , 2010, PloS one.

[15]  G. Berbers,et al.  What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[16]  H. Hallander,et al.  Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  H. Hallander,et al.  Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  M. Corbel,et al.  Characterization of Reference Materials for Human Antiserum to Pertussis Antigens by an International Collaborative Study , 2008, Clinical and Vaccine Immunology.

[19]  R. Pebody,et al.  European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations. , 2008, Vaccine.

[20]  C. Siegrist,et al.  Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. , 2008, The Journal of pediatrics.

[21]  V. Boddi,et al.  Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy , 2008, Epidemiology and Infection.

[22]  F. Noya,et al.  Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. , 2007, Vaccine.

[23]  M. Hudgens,et al.  Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants , 2007, Emerging themes in epidemiology.

[24]  J. Mertsola,et al.  Immunity to pertussis 5 years after booster immunization during adolescence. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Cherry Immunity to pertussis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Massari,et al.  How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. , 2005, Vaccine.

[27]  Seema Mattoo,et al.  Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies , 2005, Clinical Microbiology Reviews.

[28]  J. Schellekens,et al.  Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis , 2005, Epidemiology and Infection.

[29]  J. Schellekens,et al.  European Sero-Epidemiology Network: standardisation of the assay results for pertussis. , 2003, Vaccine.

[30]  L. Ravà,et al.  Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. , 2003, Pediatrics.

[31]  S. Salmaso,et al.  Pediatric sentinel surveillance of vaccine-preventable diseases in Italy , 2002, The Pediatric infectious disease journal.

[32]  E. L. Miller,et al.  The sero-epidemiology of diphtheria in Western Europe , 2000, Epidemiology and Infection.

[33]  E. Kerem,et al.  Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. , 1999, Chest.

[34]  M. Steinhoff,et al.  The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. , 1995, Pediatrics.

[35]  W. Blackwelder,et al.  Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. , 1995, Journal of immunological methods.

[36]  S. Salmaso,et al.  Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. , 1992, The Pediatric infectious disease journal.

[37]  S. Long,et al.  Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. , 1990, The Journal of infectious diseases.

[38]  M. Decker,et al.  Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. , 2018, Vaccine.

[39]  F. Noya,et al.  Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. , 2012, Vaccine.

[40]  Pertussis vaccines--WHO position paper. , 2005, Releve epidemiologique hebdomadaire.

[41]  Regina Elena Childhood vaccination coverage in Italy: results of a seven-region survey. The Italian Vaccine Coverage Survey Working Group. , 1994, Bulletin of the World Health Organization.

[42]  S. Salmaso,et al.  Childhood Vaccination Coverage in Italy: Results of a Seven-Region Survey , 1994 .